ALAMEDA, Calif. — AllCells, a Discovery Life Sciences company and provider of critical starting material and services for cell and gene therapy, announced the expansion of its apheresis network to Huntsville and Houston.
Apheresis, the removal of blood plasma from the body by its separation into plasma and cells used to remove antibodies in treating autoimmune diseases.
“This expansion is a key milestone for AllCells in our mission to become the most trusted global supplier of CGT solutions,” said Danny Zheng, president of AllCells. “Our continued investments enable us to deliver to our customers a highly characterized supply chain through a single robust and scaled resource as they pursue important breakthroughs in the field of CGT.”
AllCells provides highly characterized primary cell and tissue products, supporting global biomedical organizations seeking to develop and manufacture novel drugs and cell therapies.
With more than 3,700 CGT-focused clinical trials underway globally, the company has invested significant resources to expand collection sites and increase its apheresis capacity to meet phase-appropriate requirements.
AllCells has scaled its donor digital marketing, specialized recruiting, and event-hosting efforts, and expanded its highly experienced project management team to support new and ongoing GMP projects.
As a result, customers have access to tens of thousands of well-characterized, highly engaged, and recallable donors, coupled with in-house access to comprehensive analytical characterization, including cell biology, genomic, and proteomic capabilities.
